AMERICAN SPIKENARD FOR HOMOEOPATHIC PREPARATIONS ARALIA RACEMOSA FOR HOMOEOPATHIC PREPARATIONS

Similar documents
COMMON BARBERRY FOR HOMOEOPATHIC PREPARATIONS BERBERIS VULGARIS FOR HOMOEOPATHIC PREPARATIONS

SIMAROUBA CEDRON FOR HOMOEOPATHIC PREPARATIONS CEDRON FOR HOMOEOPATHIC PREPARATIONS

OLEANDER FOR HOMOEOPATHIC PREPARATIONS NERIUM OLEANDER FOR HOMOEOPATHIC PREPARATIONS

NEW JERSEY TEA, DRIED FOR HOMOEOPATHIC PREPARATIONS CEANOTHUS AMERICANUS SICCUM FOR HOMOEOPATHIC PREPARATIONS

COCHINEAL FOR HOMOEOPATHIC PREPARATIONS COCCUS CACTI FOR HOMOEOPATHIC PREPARATIONS

LAVENDER FOR HOMOEOPATHIC PREPARATIONS LAVANDULA VERA FOR HOMOEOPATHIC PREPARATIONS

ARNICA (WHOLE PLANT) FOR HOMOEOPATHIC PREPARATIONS ARNICA MONTANA FOR HOMOEOPATHIC PREPARATIONS

ABSINTHIUM FOR HOMOEOPATHIC PREPARATIONS ABSINTHIUM FOR HOMOEOPATHIC PREPARATIONS

ABSINTHIUM FOR HOMOEOPATHIC PREPARATIONS ABSINTHIUM FOR HOMOEOPATHIC PREPARATIONS

ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

ARTENIMOLUM ARTENIMOL. Adopted revised text for addition to The International Pharmacopoeia

Methotrexate. (Ph. Eur. monograph 0560) C 20 H 22 N 8 O Action and use. Dihydrofolate reductase inhibitor; cytostatic.

E17 ETHYLCELLULOSE. Revision 3 Stage 4

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS

Title Revision n date

RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)

Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica

Analytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products)

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

THIN LAYER CHROMATOGRAPHY

ISOMALT. Stage 4. C 12 H 24 O 11 M r C 12 H 24 O 11, 2H 2 O M r DEFINITION

Tenofovir disoproxil fumarate (Tenofoviri disoproxili fumaras)

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)

Lutein Esters from Tagetes Erecta

CELLULOSE, MICROCRYSTALLINE. Cellulosum microcristallinum. Cellulose, microcrystalline EUROPEAN PHARMACOPOEIA 7.0

CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)

Heparin Sodium ヘパリンナトリウム

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

Draft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution

EMTRICITABINE AND TENOFOVIR TABLETS

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)

PAPRIKA EXTRACT SYNONYMS DEFINITION DESCRIPTION FUNCTIONAL USES CHARACTERISTICS

FLUNITRAZEPAM Latest Revision: January 24, 2006

ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012)

REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010)

Relative Measurement of Zeaxanthin Stereoisomers by Chiral HPLC

Guide. homoeopathic preparations. for the elaboration of monographs on

Revision of monograph in the 4 th Edition of The International Pharmacopoeia (August 2008)

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)

CLINDAMYCIN PHOSPHATE (CLINDAMYCINI PHOSPHAS) REVISED DRAFT MONOGRAPH FOR INCLUSION IN The International Pharmacopoeia (August 2016)

10 Sulfaquinoxaline H N O S O. 4-amino-N-quinoxalin-2-ylbenzenesulfonamide C 14 H 12 N 4 O 2 S MW: CAS No.:

E55A GELATIN, GELLING GRADE Gelatina

ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC

TENOFOVIRI DISOPROXILIS FUMARAS TENOFOVIR DISOPROXIL FUMARATE

IDENTIFICATION AND CONTROLOFRESIDUALSOLVENTS Identification and control of residual solvents EUROPEAN PHARMACOPOEIA 6.

CYCLOSERINE Proposal for revision of The International Pharmacopoeia (August 2012)

Jagua (Genipin-Glycine) Blue (Tentative)

CLINDAMYCIN PALMITATE

Ergovaline. [Methods listed in the Feed Analysis Standards] 1 Liquid chromatography Note 1, 2 [Feed Analysis Standards, Chapter 5, Section 2

Final text for addition to The International Pharmacopoeia (June 2010)

MONOGRAPHS (NF) Pharmacopeial Forum 616 HARMONIZATION Vol. 31(2) [Mar. Apr. 2005]

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

VOLUNTARY MONOGRAPH. Council for Responsible Nutrition March 2006

19 Nosiheptide S O. For chickens (excluding broilers) For broilers. Finishing period broilers Growing period broilers. Stating chicks Growing chicks

Pectins. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016

STANDARD OPERATING PROTOCOL (SOP)

BRIEFING Assay + + +

Draft proposal for The International Pharmacopoeia

Unit I (b) Paper Chromatography

MONOGRAPHS (USP) Saccharin Sodium

» Croscarmellose Sodium is a cross linked polymer of carboxymethylcellulose sodium.

SUCROSE OLIGOESTERS TYPE I

Compliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or

Application Note Soy for Isoflavones by HPLC. Botanical Name: Glycine max L. Common Names: Parts of Plant Used: Beans.

The International Pharmacopoeia TENOFOVIR DISOPROXIL FUMARATE (JULY 2012)

ISO INTERNATIONAL STANDARD. Animal and vegetable fats and oils Determination of individual and total sterols contents Gas chromatographic method

HYDROXYPROPYLCELLULOSE, LOW SUBSTITUTED Stage 4, Revision 1 CP: USP BRIEFING NOTE

TLC SEPARATION OF AMINO ACIDS

CORESTA RECOMMENDED METHOD NÄ 9

RP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem in Pure and Pharmaceutical Formulations

Quetiapine Tablets. Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance

PROPOSAL FOR REVISION OF MONOGRAPH IN THE FOURTH EDITION OF The International Pharmacopoeia MEFLOQUINE HYDROCHLORIDE (JANUARY 2012) DRAFT FOR COMMENT

21 Virginiamycin OH O. For chickens (except for broilers) broilers. Added amount 5~15 5~15 10~20 10~20

Antioxidant. [Summary of antioxidant]

This revision also necessitates a change in the table numbering in the test for Organic Impurities.

Revision Bulletin 28 Jul Aug 2017 Chemical Medicines Monographs 3

Sucrose Esters of Fatty Acids

BRIEFING. Nonharmonized attributes: Characters, Microbial Enumeration Tests, and Tests for Specified Microorganisms, and Packing and Storage (USP)

BRIEFING. Nonharmonized attributes: Identification, Heavy metals, Characters, Labeling, Bacterial endotoxins, Sterility, Storage.

BRIEFING. 1. Definition Changed to include only Wheat Starch, as to conform to the individual monograph for Wheat Starch.

THERMALLY OXIDIZED SOYA BEAN OIL interacted with MONO- and DIGLYCERIDES of FATTY ACIDS

A high-performance liquid chromatography (HPLC) method for determination of chlorogenic acid and emodin in Yinhuang Jiangzhi Tea

1 out of 8. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 86th Meeting 2018 ERYTHROSINE

Use of degradable cationic surfactants with cleavable linkages for enhancing the. chemiluminescence of acridinium ester labels. Supplementary Material

» Monohydrate Citric Acid contains one molecule of water of hydration. It contains not less than 99.5 percent and not more than 100.

Most of the ethanol that is used as a biofuel in this country is produced from corn.

Supporting Information for. Boronic Acid Functionalized Aza-Bodipy (azabdpba) based Fluorescence Optodes for the. analysis of Glucose in Whole Blood

Phrmacognostical & Pharmaceutical study

Pharmacopeial Forum 818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA

Development and Validation of Stability Indicating HPTLC Method for Estimation of Seratrodast

3-Acetyldeoxynivalenol. 15-Acetyldeoxynivalenol

INTERIM REVISION ANNOUNCEMENT

ISOMALT. Chemical formula 6-O-alpha-D-Glucopyranosyl-D-sorbitol: C 12 H 24 O 11 1-O-alpha-D-Glucopyranosyl-D-mannitol dihydrate: C 12 H 24 O 11 2H 2 O

A PRELIMINARY STANDARD FOR SURADARULEPA CHURNA - AN AYURVEDIC PREPARATION

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

Transcription:

AMERICAN SPIKENARD FOR HOMOEOPATHIC PREPARATIONS ARALIA RACEMOSA FOR HOMOEOPATHIC PREPARATIONS Aralia racemosa ad praeparationes homoeopathicas DEFINITION Dried, underground part of Aralia racemosa L. Content: minimum 0.10 per cent of chlorogenic acid (C 16 H 18 O 9 ; M r 354.3) (dried drug). IDENTIFICATION A. Fleshy, fibrous rhizome, whitish to pale brown outside, irregularly cylindrical, tuberous in places, ramified measuring up to 40 cm long and usually 10-50 mm in diameter. More or less ramified roots, 5-25 mm in diameter and measuring up to 25 cm long, inserted at the level of the annular nodes. More or less concave scars on the upper part of the rhizome, due to the fall of the leaves. B. Reduce the underground part to a powder (355). The powder is yellowish-brown. Examine under a microscope, using chloral hydrate solution R. The powder presents scarce fragments of suber composed of superposed polyhedral cells; fragments of parenchyma consisting of ovoid cells, some of them containing calcium oxalate clusters; secretory canals, most often fragmented; fragments of pitted or reticulate vessels; calcium oxalate clusters. Examine under a microscope using glycerol (50 per cent V/V) R. The powder presents starch granules; spherical and isolated, about 10 µm in diameter. C. Thin-layer chromatography (2.2.27).. Add 30 ml of ethanol (65 per cent V/V) R to 3 g of powdered drug (355). Heat under a reflux condenser at 60 C for 15 min. Allow to cool. Filter.. Dissolve 5 mg of chlorogenic acid R and 5 mg of caffeic acid R in 20 ml of Mobile phase: anhydrous formic acid R, water R, ethyl acetate R (10:10:80 V/V/V). Application: 20 µl [or 10 µl] as bands. Development: over a path of 10 cm [or 6 cm]. Detection: examine in ultraviolet light at 365 nm.

Results: see below the sequence of fluorescent zones present in the chromatograms obtained with the reference solution and the test solution. Furthermore other faint, fluorescent zones may be present in the chromatogram obtained with the test solution. Caffeic acid: a blue zone Chlorogenic acid: a greenish-blue zone A greenish-blue zone (chlorogenic acid) A greenish-blue zone D. Thin-layer chromatography (2.2.27).. Add 30 ml of ethanol (65 per cent V/V) R to 3 g of powdered drug (355). Heat under a reflux condenser at 60 C for 15 min. Allow to cool. Filter.. Dissolve 10 mg of oleanolic acid R and 10 mg of cholesterol R in 30 ml of Mobile phase: acetone R, methylene chloride R (10:90 V/V). Application: 30 µl [or 20 µl] as bands. Development: over a path of 10 cm [or 7 cm]. Detection: spray with anisaldehyde solution R and heat at 100-105 C for 10 min. Examine in daylight. Results: see below the sequence of zones present in the chromatograms obtained with the reference solution and the test solution. Furthermore other faint zones may be present in the chromatogram obtained with the test solution. An intense, spread out violet zone Cholesterol: a purple zone A purplish-blue zone A more or less intense purplish-blue zone Oleanolic acid: a purplish-pink zone 2

3 TESTS Loss on drying (2.2.32): maximum 11.0 per cent, determined on 1.0 g of powdered drug (355) by drying in an oven at 105 C for 2 h. Total ash (2.4.16): maximum 10.0 per cent, determined on 1.0 g of powdered drug (355). ASSAY Liquid chromatography (2.2.29).. Place 2.500 g of powdered drug (355) and 40 ml of ethanol (60 per cent V/V) R into a 250 ml flask. Heat under a reflux condenser for 30 min. Allow to separate then filter into a 100.0 ml volumetric flask. Add 40 ml of ethanol (60 per cent V/V) R to the residue and heat again under a reflux condenser for 30 min. Filter, rinse the flask and the filter with ethanol (60 per cent V/V) R and transfer into the 100.0 ml volumetric flask. After cooling, dilute to 100.0 ml with ethanol (60 per cent V/V) R.. In a 100.0 ml volumetric flask, dissolve 20.0 mg of chlorogenic acid CRS and 20.0 mg of rosmarinic acid R in ethanol (60 per cent V/V) R and dilute to 100.0 ml with the same solvent. Take 7.0 ml of this solution and dilute to 20.0 ml with ethanol (60 per cent V/V) R. Column: - size: l = 0.25 m, Ø = 4 mm, - stationary phase: end-capped, octylsilyl silica gel for chromatography R (5 µm); porosity 10 nm, specific surface 350 m²/g, carbon rate 12.5 %, - temperature: 30 C. Mobile phase: - mobile phase A: glacial acetic acid (10 per cent V/V) R, - mobile phase B: methanol R. Flow rate: 1.0 ml/min. Time (min) Mobile phase A Mobile phase B 0-10 100 0 0 100 10-20 0 100 Detection: spectrophotometer at 326 nm. Injection: 10 µl. Retention time of chlorogenic acid: about 6 min, of rosmarinic acid: about 8 min.

4 System suitability: - resolution: minimum 5 between the peaks due to chlorogenic acid and rosmarinic acid in the chromatogram obtained with the reference solution. Calculate the percentage content of chlorogenic acid, from the expression: A1 m2 0.35 p A m 2 A 1 = area of the peak due to chlorogenic acid in the chromatogram obtained with the test solution, A 2 = area of the peak due to chlorogenic acid in the chromatogram obtained with the reference solution, m 1 = mass of the drug sample, in grams, m 2 = mass of the sample of chlorogenic acid, in grams, p = percentage content of chlorogenic acid in chlorogenic acid CRS. 1 STOCK DEFINITION American spikenard mother tincture is prepared with ethanol (65 per cent V/V), using the dried underground part of Aralia racemosa L. Content: minimum 0.006 per cent m/m of chlorogenic acid (C 16 H 18 O 9 ; M r 354.3). PRODUCTION Method 1.1.10 (2371).Drug fragmented into 2-6 cm long segments. Maceration time: 3-5 weeks. CHARACTERS Appearance: yellow liquid. Specific fragrance remembering wax. IDENTIFICATION A. Thin-layer chromatography (2.2.27).. Mother tincture.. Dissolve 5 mg of chlorogenic acid R and 5 mg of caffeic acid R in 20 ml of

5 Mobile phase: anhydrous formic acid R, water R, ethyl acetate R (10:10:80 V/V/V). Application: 20 µl [or 10 µl] as bands. Development: over a path of 10 cm [or 7 cm]. Detection: examine in ultraviolet light at 365 nm. Results: see below the sequence of fluorescent zones present in the chromatograms obtained with the reference solution and the test solution. Furthermore other faint, fluorescent zones may be present in the chromatogram obtained with the test solution. Caffeic acid: a blue zone Chlorogenic acid: a greenish-blue zone A greenish-blue zone (chlorogenic acid) A greenish-blue zone B. Thin-layer chromatography (2.2.27).. Mother tincture.. Dissolve 10 mg of oleanolic acid R and 10 mg of cholesterol R in 30 ml of Mobile phase: acetone R, methylene chloride R (10:90 V/V). Application: 30 µl [or 10 µl] as bands. Development: over a path of 10 cm [or 7 cm]. Detection: spray with anisaldehyde solution R and heat at 100-105 C for 10 min. Examine in daylight. Results: see below the sequence of zones present in the chromatograms obtained with the reference solution and the test solution. Furthermore other faint zones may be present in the chromatogram obtained with the test solution.

An intense, spread out violet zone Cholesterol: a purple zone A purplish-blue zone Oleanolic acid: a purplish-pink zone 6 TESTS Ethanol (2.9.10): 60 per cent V/V to 70 per cent V/V. Dry residue (2.8.16): minimum 1.5 per cent m/m. ASSAY Liquid chromatography (2.2.29).. In a 20.0 ml volumetric flask, place 10.00 g of mother tincture and dilute to 20.0 ml with ethanol (60 per cent V/V) R. Filter.. In a 100.0 ml volumetric flask, dissolve 20.0 mg of chlorogenic acid CRS and 20.0 mg of rosmarinic acid R in ethanol (60 per cent V/V) R and dilute to 100.0 ml with the same solvent. Take 5.0 ml of this solution and dilute to 20.0 ml with ethanol (60 per cent V/V) R. Column: - size: l = 0.25 m, Ø = 4. mm, - stationary phase: end-capped, octylsilyl silica gel for chromatography R (250 x 4 mm, 5 µm), porosity 10 nm, specific surface 350 m²/g, carbon rate 13 %. - temperature: 30 C. Mobile phase: - mobile phase A: glacial acetic acid (10 per cent V/V) R. - mobile phase B: methanol R. Flow rate: 1.0 ml/min. Time (min) Mobile phase A Mobile phase B 0-10 100 0 0 100 10-20 0 100 Detection: spectrophotometer at 326 nm. Injection: 10 µl.

System suitability: - resolution: minimum 5 between the peaks due to chlorogenic acid and rosmarinic acid in the chromatogram obtained with the reference solution. Calculate the percentage content m/m of chlorogenic acid, from the expression: A1 m2 0.05 p A m 2 A 1 = area of the peak due to chlorogenic acid in the chromatogram obtained with the test solution, A 2 = area of the peak due to chlorogenic acid in the chromatogram obtained with the reference solution, m 1 = mass of the mother tincture sample, in grams, m 2 = mass of the sample of chlorogenic acid, in grams, p = percentage content of chlorogenic acid in chlorogenic acid CRS. 1 7